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Abstract 
Targeting neuroactive steroid biosynthetic pathway by specific 18 kDa Translocator Protein (TSPO) 
ligands may represent a therapeutic approach in a variety of neurodegenerative and neuropsychiatric 
diseases. However, the lack of correlation between the binding affinity and the in vitro steroidogenic 
efficacy has limited the identification of lead compounds by a traditional affinity-based drug 
discovery strategy. Our recent researches indicate that the key factor for robust steroidogenic TSPO 
ligand efficacy is not the binding affinity per se, but rather the time the compound spends into the 
target, namely its Residence Time (RT). The assessment of this kinetic parameter during the in vitro 
characterization of compounds appears mandatory in order to obtain structure-efficacy relationships 
suitable for the future development of novel molecules with promising pharmacological properties.  
 
 
.  
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Neuroactive steroids are endogenous neuromodulators that, by binding to membrane receptors 
and tuning gene expression via intracellular receptors, regulate many physiological functions. They 
can be synthesized in the brain de novo, so that they were termed neurosteroids, or reach the central 
nervous system (CNS) from peripheral steroidogenic organs, such as adrenals and gonads, and are 
locally metabolized. Neurosteroids levels are altered in several psychiatric and neurodegenerative 
diseases as a consequence of an impairment of neurosteroidogenesis; both preclinical and clinical 
studies emphasize a therapeutic potential of neuroactive steroids for these diseases, whereby 
symptomatology ameliorates upon restoration of neuroactive steroid concentrations.[1-3]  
Actually, neuroactive steroids exert potent anxiolytic, antidepressant, anticonvulsant, sedative, 
analgesic and amnesic effects, mainly acting as positive allosteric modulators at specific sites on the 
-subunit of the γ-amino-butyric acid type A receptor (GABAAR).[4] In addition, neuroactive steroids 
exert neuroprotective, neurotrophic, anti-inflammatory and antiapoptotic activities in several animal 
models of traumatic brain and spinal cord injury, cerebral ischemia, peripheral neuropathy, and 
neurodegenerative diseases (i.e. Alzheimer’s and Parkinson’s diseases, multiple sclerosis, etc...).[2] 
However, direct administration of neuroactive steroids has several challenges, including short 
half-life, low bioavailability, poor aqueous solubility, development of tolerance, undesired effects 
such as sedation and memory impairment that limit their therapeutic use. Consequently, modulation 
of neurosteroidogenesis to restore the altered endogenous neuroactive steroid tone may represent a 
better therapeutic approach.[1-3] 
Neuroactive steroid biosynthetic pathway may be targeted at different levels in order to promote 
neurosteroidogenesis,[3] including the Translocator Protein 18 kDa (TSPO), an outer mitochondrial 
membrane protein expressed at high levels in peripheral and CNS steroid-producing cells.[5] 
TSPO plays a key role in the rate-limiting step of neuroactive steroid synthesis, consisting of 
cholesterol translocation into mitochondrion in order to supply it to the cytochrome P450 enzyme 
CYP11A1 for the conversion into pregnenolone, the precursor of all neurosteroids.[6] 
Numerous TSPO ligands resulted able to potently and dose-dependently stimulate steroid 
biosynthesis in steroidogenic cells, and they have been proposed as innovative therapeutic tools in 
several pathological conditions, due to their neuroprotective, anxiolytic, anti-inflammatory, and 
regenerating properties in different in vitro and in vivo models.[7-10] To date, phase II clinical trials 
have been concluded for the treatment of diabetic peripheral neuropathy (ClinicalTrials.gov 
identifier: NCT00502515), and generalized anxiety disorder (NCT00108836).[11,12] 
Since identification of TSPO by means of the benzodiazepines diazepam and Ro5-4864 (1) 
(Figure 1),[13] structurally different classes of highly potent and selective TSPO ligands have been 
reported,[14] including the isoquinolinecarboxamides, of which the 1-(2-chlorophenyl)-N-methyl-N-
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(1-methylpropyl)-1-isoquinolinecarboxamide (PK11195, 2, Figure 1) is widely considered as a 
prototypical TSPO ligand,[15] imidazopyridines (alpidem),[16] indoleacetamides (FGIN-1-27),[17] 
aryloxyanilides,[18] 4-phenylquinazolines,[19,20] and purineacetamides (XBD173, also called AC-5216 
13, vide infra).[11,12]  
In this context, we disclosed a class of potent and selective TSPO ligands, the N,N-dialkyl-2-
phenylindol-3-ylglyoxylamides (PIGAs, 3-12, Figure 1), the majority of which showed Ki values in 
the nanomolar/subnanomolar range; moreover, a number of compounds were able to stimulate 
effectively steroid biosynthesis.[21-23] 
In two recent studies, a number of our PIGA ligands promoted the well-being of human 
astrocytes and prevented oxidative damage and inflammatory response in an in vitro 
neuroinflammatory model, suggesting these compounds could represent potential new therapeutic 
tools for the treatment of inflammatory-based neuropathologies and/or for CNS diseases 
characterized by astrocyte loss. Interestingly, in both cases the observed effects were completely 
counteracted by the co-treatment with DL-aminoglutethimide, an inhibitor of P450scc, supporting 
the hypothesis that the PIGA-mediated protective mechanisms were mainly related to steroid 
production.[25,26]  
Furthermore, some PIGA compounds have been evaluated in vivo for their anxiolytic properties 
by means of the elevated plus-maze (EPM) tests in rats. Two compounds significantly affected rats’ 
performance, leading to an increase in both entries and time spent in the open arms, with no effect on 
rats’ spontaneous exploratory activity, evidencing promising anxiolytic/non sedative properties. 
Investigations on the mechanism of action by which PIGAs exert their anxiolytic activity indicate 
that it involves the stimulation of endogenous neurosteroid production, which in turn determines a 
positive modulation of GABAAR activity.
[22,24]  
However, one of the most recurrently issue concerning TSPO ligands consists in the lack of 
correlation between the binding affinity and the in vitro efficacy, including steroidogenic efficacy. 
This represents a very crucial point, because this phenomenon has limited not only the identification 
of lead compounds by a traditional affinity-based drug discovery strategy, but also questioned the 
specificity of the observed effects.[27]  
This is one of the most recurrent issue concerning TSPO ligands[27] and it’s evident also within 
the PIGA class, with derivatives that, despite a very similar binding affinity, showed a great difference 
in steroidogenic efficacy, measured as the ability to stimulate in vitro pregnenolone formation. 
Analogously, compounds with a comparable efficacy show a discrepancy in Ki values.
[21-23]  
Recent studies have shown that the affinity of a ligand for its target could not directly define its 
biological effectiveness that may instead be related to the period that a drug resides on its target after 
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binding, namely its ‘Residence Time’ (RT).[28] In principle, the lifetime of the binary drug-target 
complex is determined by two rate constants, the association rate constant (Kon), and the dissociation 
rate constant (Koff), but the slow drug-target dissociation seemed to be the main critical molecular 
determinant for pharmacological activity. The relevance of RT, which is defined as the reciprocal of 
Koff, as a key factor for successful lead optimization processes has been documented for other ligand-
target systems, including antagonists of adenosine A2A and muscarinic M3 receptors, several kinase 
inhibitors, HIV protease inhibitors, and so on.[28]  
Thus, very recently we set up a kinetic radioligand binding assay for TSPO ligand RT 
determination.[29] A number of our previous reported TSPO ligands, belonging from the 2-
phenylindolylglyoxylamide class (PIGAs), was selected based on their different abilities to stimulate 
in vitro steroidogenesis, compounds 3-12 Table 1.[21-23] Among such selected TSPO compounds, 
ligands possessing anxiolytic effects or in vitro pleiotropic and anti-inflammatory properties, as well 
as classical TSPO ligands 1 and 2 were included.  
 
Compd. R5 Ar R1 R2 
3 (PIGA719)[a] H C6H5 (CH2)2CH3 (CH2)2CH3 
4 (PIGA720)[a] H C6H5 (CH2)5CH3 (CH2)5CH3 
5 (PIGA745)[a] Cl C6H5 (CH2)5CH3 (CH2)5CH3 
6 (PIGA823)[b,c] Cl C6H4-4-Cl CH2CH3 CH2C6H5 
7 (PIGA835)[a] Cl C6H4-4-Cl (CH2)3CH3 (CH2)3CH3 
8 (PIGA839)[a,d] H C6H4-4-CH3 (CH2)2CH3 (CH2)2CH3 
9 (PIGA925)[b] NO2 C6H5 (CH2)5CH3 (CH2)5CH3 
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10 (PIGA1128)[e] H naphth-2-yl- (CH2)2CH3 (CH2)2CH3 
11 (PIGA1138)[e,f] H naphth-2-yl- CH3 (CH2)4CH3 
12 (PIGA1214)[e] H C6H4-4-COOH (CH2)5CH3 (CH2)5CH3 
[a] ref [21]; [b] ref [22]; [c] ref [25]; [d] ref [24]; [e] ref [23]; [f] ref [26] 
Figure 1. Structures of Ro5-4864 (1), PK11195 (2), PIGAs (3-12), XBD173 (13), and Etifoxine (14). 
To this aim, kinetic experiments were performed to measure Kon and Koff rate constants for each 
compound at [3H]-2 binding site, and their RT was calculated.[29] As it should be noted from the data 
reported in Table 1, the majority of the tested compounds resulted rapid dissociating competitors of 
2 binding site (3, 4, 5, 7, 9, 12 and the reference 1). Conversely, compounds 6, 8, 10, and 11 were 
slow dissociating competitors.  
 
Table 1. Experimental thermodynamic/kinetic data and steroidogenic parameter for Ro5-4864 (1), 
PK11195 (2), PIGAs (4-13), and XBD173 (14).  
TSPO ligand Equilibrium Ki 
(nM) 
RT 
(min) 
Emax 
(at 100 µM) 
(vehicle set to 100%) 
1[a] 20.0 ± 2.0 32 ± 3 150 ± 4 
2[a] 3.30 ± 0.3 34 ± 3 153 ± 4  
3[a,b] 12.2 ± 1.0 11 ± 2 146 ± 2 
4[a,b] 1.40 ± 0.2 26 ± 2 144 ± 4 
5[a,b] 13.1 ± 1.1 17 ± 1 140 ± 5 
6[a,c] 3.30 ± 0.3 127 ± 4 272 ± 11 
7[a,b] 0.91 ± 0.1 17 ± 1 149 ± 4 
8[a,b] 5.50 ± 0.4 109 ± 4 254 ± 5 
9[a,c] 12.2 ± 3.1 15 ± 2 166 ± 5 
10[a,d] 0.31 ± 0.02 55 ± 2 179 ± 7 
11[a,d] 0.34 ± 0.03 141 ± 4 275 ± 5 
12[a,d] 343.01 ± 15.94 39 ± 2 141 ± 4 
13[e] 2.41 127  245 ± 17 
data from ref.: [a], [29]; [b], [21]; [c], [22]; [d], [23]; [e], [31] 
Notably, correlation analysis of the obtained results showed a highly significant positive 
correlation between the kinetic parameter RT and the compounds’ efficacy (Emax) to stimulate in vitro 
steroidogenesis (Figure 2A).[29] In addition, highly significant correlation resulted also between the 
logarithm of RT and the area under the dose-response curve (AUC), a value that combines potency 
and efficacy of a drug into a single parameter (Figure 2B). On the contrary, no correlation was 
observed between these same parameters and the logarithm of Ki values (Figure 2C).
[29]  
 
6 
 
 
 
Figure 2. Correlation analyses between kinetic/thermodynamic and steroidogenic parameters. TSPO 
compound names were included next to their respective data points (for PIGA compounds the ID 
numbers were shown). (A) Scatter plot of the Emax values against kinetic parameters (log RT) of test 
TSPO ligands; (B) Scatter plot of the AUC values against kinetic parameters (log RT) of test TSPO 
ligands; (C) Scatter plot of the Emax values against thermodynamic parameters (log Ki) of test TSPO 
ligands. Adapted from ref [29]. 
 
From a therapeutic perspective, the “high neurosteroidogenic” 6 and 8 derivatives, characterized 
by long RT and high Emax (6: RT = 127 min, Emax = 272%; 8: RT = 109 min; Emax = 254%), elicited 
a significant anxiolytic activity in the EPM paradigm in rat.[22,24] Consistently, 1 and 2 , which have 
been documented without anxiolytic activity in EPM test,[30] showed short RT and low Emax (1: RT= 
32 min; Emax = 150%; 2: RT= 34 min, Emax = 153%).
[29]  
Our hypothesis assessing that RT could be a metric of promising anxiolytic activities of a TSPO 
ligand found further support by very recent works, in which we retrospectively evaluate the RT and 
the relationship with steroidogenic activity of known anxiolytic TSPO ligands 13[31] and Etifoxine 
(14)[32] (Figure 1, Table 1). This latter is a clinically approved drug for the treatment of anxiety-related 
disorders (Stresam, Biocodex, Gentilly, France).  
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Also for such compounds, a discrepancy between the affinity at [3H]-2 binding site and ability 
to enhance neurosteroid synthesis has been recently documented[33] and confirmed by us.[31,32] 
Specifically, although 13 and 14 are both highly potent to stimulate neurosteroidogenesis, 14 shows 
a very lower binding affinity to [3H]-2 site than 13, questioning the specific contribution of TSPO in 
mediating 14 neurosteroidogenic efficacy.  
When 13 was evaluated by kinetic assays using [3H]-2, an approximately 4-fold longer RT (127 
min) than [3H]-2 was derived (Table 1); consistently, 13 stimulated efficaciously 
neurosteroidogenesis, with Emax 245 ± 17% (Table 1), value comparable to that of the “high 
steroidogenic” PIGAs exhibiting anxiolytic effects in rats.[31] 
In similar experiments, 14 induced a dose-dependent pregnenolone production (Emax 235 ± 18 
%), combined with a surprising short RT at PK11195 (2) binding site (RT 15 ± 2 min), a value in line 
with RTs of “low neurosteroidogenic” ligands. This unexpected result prompted us to consider the 
existence on TSPO of two heterogeneous sites for reference ligands 1 and 2, either partially 
overlapping or allosterically coupled.[34] At [3H]-1 binding site, 14 competitively bound with a low 
affinity (approximately 800-fold lower than 1) and a long RT (RT 50 ± 5 min, approximately 3-fold 
longer than 1).[32] 
Based on these results, it might be proposed that an efficacious pharmacological stimulation of 
neurosteroidogenesis could be obtained by the use of a TSPO ligand that interacts with a long 
residence time at PK11195 (at least 100 min) or at Ro5-4864 (at least 50 min) binding site. This has 
important implications, as the pharmacological stimulation of neurosteroidogenesis via TSPO could 
represent a suitable strategy to obtain promising anxiolytic agents, devoid of the typical adverse 
effects of benzodiazepines.  
In conclusion, the lack of correlation between the compound binding affinity and the 
steroidogenic efficacy evidences the limitation of an affinity-based structure-activity relationships 
(SAR) strategy for the identification of effective TSPO ligands. Conversely, the time spent by a drug 
into its target (RT) represent a critical predictor for in vitro and, most importantly, in vivo efficacy. 
These findings represent a significant advancement in the TSPO medicinal chemistry field, 
highlighting that structure-efficacy relationships studies based on kinetic parameters are a more 
suitable approach for the development of novel compounds with promising pharmacological 
properties. 
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Neurosteroidogenic efficacy of Translocator Protein (TSPO) ligands can be predicted by evaluating the time 
that the ligand spent into the target, namely the Residence Time, rather than the binding affinity, aiding the 
development of novel compounds with promising pharmacological properties and therapeutic potential. 
